Anagrelide treatment in early pregnancy in a patient with JAK2V617F-positive essential thrombocythemia: case report and literature review

Sobas, Marta Anna; Pérez Encinas, Manuel Mateo; Rabuñal Martínez, María; Quinteiro García, Celsa; Bello López, José Luis
Thumbnail
Estatísticas
Estatísticas
Identificadores
Identificadores
URI: http://hdl.handle.net/20.500.11940/22721
PMID: 19887779
ESSN: 1421-9662
Rexistro completo
Servizos
Servizos
RISMendeleyLinksolver
Visualización ou descarga de ficheiros
Visualización ou descarga de ficheiros
Data de publicación
2009
Título da revista
Acta Haematologica
Tipo de contido
Artigo
DeCS
resultado del embarazo | complicaciones hematológicas del embarazo | embarazo | quinazolinas | trombocitemia esencial | recién nacido
MeSH
Pregnancy | Quinazolines | Infant, Newborn | Thrombocythemia, Essential | Female | Pregnancy Complications, Hematologic | Women | Pregnancy Outcome
CIE
Trombocitemia idiopática (D47.3)
Resumo
[EN] Essential thrombocythemia (ET) has 2 peaks of incidence: one is at 60 years of age, the other at 30 years. In women, the peak at the earlier age presents challenges for management in Nevertheless, HDU and ANA are not recommended during pregnancy because of embryo/ fetotoxic effects observed in animals . There are scarce clinical data on adverse incidents when ANA is used during pregnancy in humans. We present a successful outcome of a 32-year-old woman with ET who was treated with ANA before becoming pregnant and during early pregnancy.